BLAINJECTIONINJECTABLE
Approved
Mar 2019
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
5/8 — Partial
TRAZIMERA (trastuzumab-qyyp) by Pfizer is her2/neu/cerbb2 antagonists [moa]. Approved for breast cancer. First approved in 2019.
TRAZIMERA (trastuzumab-qyyp) is a monoclonal antibody biosimilar to Herceptin that targets HER2/neu receptors on cancer cells, blocking growth signals and triggering immune-mediated cell death. It is indicated for HER2-positive breast cancer and gastric cancer patients. This is a reference-priced biologic in a crowded competitive segment.
$0.005BPart D
PeakProduct is at peak commercial maturity with modest Medicare spending; team focus is on maintaining market access and share against multiple biosimilar competitors.
Mechanism of Action
HER2/Neu/cerbB2 Antagonists
Pharmacologic Class:
HER2/neu Receptor Antagonist
Indications (1)
Why This Matters for Your Career
Worked on TRAZIMERA at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.